Literature DB >> 27908223

Proteomic profiling in plasma cell disorders: a feasibility study.

Sham Mailankody1,2, Sean M Devlin3, Neha Korde1,2, Nikoletta Lendvai1,2, Alexander Lesokhin1,2, Heather Landau2,4, Hani Hassoun1,2, Andrea Ballagi5, Daniel Ekman5, David J Chung2,4, Minal Patel6, Guenther Koehne2,4, Sergio Giralt2,4, Ola Landgren1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27908223      PMCID： PMC5587169          DOI： 10.1080/10428194.2016.1258699

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

Review 1.  Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.

Authors:  Sham Mailankody; Esther Mena; Constance M Yuan; Arun Balakumaran; W Michael Kuehl; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2010-10-20

2.  Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting.

Authors:  Hongda Chen; Manuela Zucknick; Simone Werner; Phillip Knebel; Hermann Brenner
Journal:  Clin Cancer Res       Date:  2015-05-26       Impact factor: 12.531

3.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

4.  Expression of VEGF and its receptors by myeloma cells.

Authors:  S Kumar; T E Witzig; M Timm; J Haug; L Wellik; R Fonseca; P R Greipp; S V Rajkumar
Journal:  Leukemia       Date:  2003-10       Impact factor: 11.528

5.  Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.

Authors:  Benjamin M Cherry; Neha Korde; Mary Kwok; Elisabet E Manasanch; Manisha Bhutani; Marcia Mulquin; Diamond Zuchlinski; Mary Ann Yancey; Irina Maric; Katherine R Calvo; Raul Braylan; Maryalice Stetler-Stevenson; Constance Yuan; Prashant Tembhare; Adriana Zingone; Rene Costello; Mark J Roschewski; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2013-07-29

6.  Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.

Authors:  John M L Ebos; Christina R Lee; Elena Bogdanovic; Jennifer Alami; Paul Van Slyke; Giulio Francia; Ping Xu; Anthony J Mutsaers; Daniel J Dumont; Robert S Kerbel
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701
  6 in total
  4 in total

1.  VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.

Authors:  Oisun Jung; DeannaLee M Beauvais; Kristin M Adams; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2019-10-28       Impact factor: 5.285

2.  Proteomics-inspired precision medicine for treating and understanding multiple myeloma.

Authors:  Matthew Ho; Giada Bianchi; Kenneth C Anderson
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-24

Review 3.  Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders.

Authors:  Sridurga Mithraprabhu; Maoshan Chen; Ioanna Savvidou; Antonia Reale; Andrew Spencer
Journal:  Leukemia       Date:  2021-07-14       Impact factor: 11.528

4.  Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples.

Authors:  Florentin Späth; Carl Wibom; Esmeralda J M Krop; Antonio Izarra Santamaria; Ann-Sofie Johansson; Ingvar A Bergdahl; Johan Hultdin; Roel Vermeulen; Beatrice Melin
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.